Skip to content
Search

Latest Stories

UKHSA and ONS launch Winter COVID-19 Infection Study

The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter.

The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2).


UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University, analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023.

Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader community. The sample will be structured to broadly reflect key population characteristics.

Though widespread vaccination has enabled us to coexist with COVID-19, certain individuals still face a higher risk of severe illness. Consequently, this can place added strain on the NHS during the winter months, the UKHSA said in a statement.

That's why the UKHSA is urging eligible adults to schedule their flu and COVID-19 vaccines online via the NHS website, or by using the NHS App, the statement added. Patients can also call 119 for free if they're unable to go online. This provides them with the best protection against severe illness and hospitalisation, the UKHSA said.

UKHSA's current surveillance systems offer real-time data on hospital and ICU admission rates. However, the implementation of this study will enable it to identify shifts in the Infection Hospitalisation Rate (IHR), necessitating precise measurement of infection levels within the community.

By calculating the IHR, UKHSA can evaluate the potential for heightened demand on healthcare services stemming from shifts in the virus's transmission patterns, which might be influenced by the emergence of new variants.

“The data we collected alongside the ONS during the pandemic provided us with a huge amount of valuable insight, so I am delighted that we are able to work together again to keep policymakers and the wider public informed in the coming months,” said Professor Steven Riley, Director General of Data, Analytics and Surveillance at the UK Health Security Agency.

“UKHSA continues to lead the way internationally on COVID-19 surveillance and by re-introducing a study of positivity in the community, we can better detect changes in the behaviour of the virus,” he added.

The study will utilise UKHSA Lateral Flow Devices (LFDs). The latest UKHSA technical briefing, published on 21 September, included initial findings of tests performed in the laboratory at Porton Down to examine the effectiveness of LFDs in detecting BA.2.86, and found no reduction in sensitivity compared to previous variants. The model and scale of this study could also be converted into a programme that captures data on different respiratory viruses, should that be required in future.

“ONS is committed to building on the experience of standing up the gold standard Covid Infection Survey,” said Emma Rourke, Deputy National Statistician, at the Office for National Statistics. “Our resources and statistical expertise are here for the public good, and we are delighted to be delivering this study in partnership with the UKHSA. There remains a need for robust data to help us continue to understand the virus and its effects during the winter months.”

“As well as working to provide UKHSA with regular rates of positivity, we will also be looking at analysis of symptoms, risk factors and the impact of respiratory infections, including long covid, as part of this important surveillance,” Emma added.

In September, the International Pharmaceutical Federation released a new policy statement advocating for a "life-course" approach to vaccination by pharmacists. This approach supports extending vaccine schedules and strategies, enabling individuals of all age groups to receive vaccinations throughout their entire lifespan, from infancy through to old age. It emphasises prioritising an individual's health and well-being, including a comprehensive vaccination regimen administered across their entire life span.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less